Can Mounjaro Affect Your Period?

Weight loss as the likely driver, what the trial data shows

The SURMOUNT-1 trial, published in the New England Journal of Medicine, enrolled over 2,500 adults and recorded average body-weight reductions of around 20–21% at the highest dose over 72 weeks. That scale of loss, achieved relatively quickly, is exactly the kind of physiological shift known to alter hormonal balance. Adipose tissue is not passive storage, it synthesises and releases oestrogen. When fat stores fall quickly, oestrogen levels can dip, and the hypothalamic-pituitary-ovarian axis responds by changing the frequency or intensity of ovulation. The result can be irregular, lighter, heavier or temporarily absent periods, and many women find it helpful to read about whether Mounjaro can affect your periods before they begin treatment.

This is a question our prescribers hear most weeks, and the honest answer is that the evidence points to weight loss as the mechanism rather than tirzepatide acting directly on reproductive hormones. The Mounjaro SmPC does not list menstrual irregularity under its side-effect profile, which reflects what the manufacturer's clinical trials captured formally. Real-world experience is broader, and women who want more detail can explore how tirzepatide may affect your period for a closer look at the evidence. Women who have lost similar amounts of weight through other routes report comparable cycle changes, which supports the weight-loss-driven explanation.

It is worth noting that for some women with polycystic ovary syndrome, weight loss can actually regularise periods that were previously disrupted. So the direction of change is not uniform, it depends on where you are starting from, and our page on whether Mounjaro affects your period covers this variability in more detail.

The contraceptive pill: a specific interaction to know about

There is one Mounjaro-specific concern that goes beyond general weight-loss effects, and it matters if you rely on oral contraception. Tirzepatide slows gastric emptying as part of how it reduces appetite. Slower gastric emptying means the oral contraceptive pill may be absorbed less reliably, particularly in the early weeks of treatment and around each dose increase when the gastric-slowing effect is greatest.

NHS England's guidance on weight-management injections is explicit on this point: women using oral contraceptives should add a non-oral method, such as condoms, for the first four weeks of Mounjaro treatment and for four weeks after every dose increase. This is not a theoretical caution, it is the standard clinical recommendation in UK prescribing. The same guidance notes that no equivalent absorption concern has been identified for injectable semaglutide. If you are on the pill and considering tirzepatide, this is something to raise at your consultation, and our dedicated page on taking Mounjaro on your period addresses some of the practical timing questions that come up here. You can read more about how tirzepatide works as a dual GIP and GLP-1 receptor agonist and why the gastric-emptying effect sits at the centre of several practical questions like this one.

If you use a patch, hormonal coil, implant or injection for contraception, the absorption issue does not apply, those routes bypass the gut entirely.

When a change to your cycle needs medical attention

Most cycle changes in the first few months of Mounjaro treatment are benign and self-limiting as the body adjusts to a lower weight. A shorter or longer cycle, one missed period, or a lighter bleed than usual is unlikely to be alarming in that context. That said, some changes do warrant a conversation with a clinician.

Contact your GP or prescriber if: periods stop for more than two or three months consecutively; you develop unusually heavy or prolonged bleeding; you experience pelvic pain that is new or worsening; or you are concerned about fertility. These symptoms are not typical weight-loss effects and need individual assessment. Mounjaro is not recommended during pregnancy, while breastfeeding, or if you are actively trying to conceive, so if your contraceptive situation is uncertain during treatment, that is a clinical priority, not a minor detail. You can also report any unexpected side effect through the MHRA Yellow Card scheme, which helps build the evidence base for medicines in real-world use.

The full Mounjaro overview covers what else to expect during treatment. For a broader look at the considerations before starting, the treatment overview sets out the eligibility picture clearly.

Getting the right clinical input before and during treatment

Because the relationship between Mounjaro and menstrual cycles runs through weight loss rather than direct hormonal action, there is no one-size-fits-all prediction of what will happen to your cycle. Someone losing 5% of body weight over six months will have a different experience from someone losing 20% over the same period. Starting weight, ovarian reserve, any underlying conditions like PCOS or thyroid disease, and contraceptive method all feed into what you might notice.

This is exactly the kind of nuance a clinical consultation is designed to surface. At nume, a GPhC-registered Independent Prescriber reads your full health history (not software, not an automated screen) before any prescription is considered. If menstrual health is relevant to your assessment, it forms part of that conversation. The about us page explains how the service works, and our clinical team is available to answer questions throughout treatment, not just at the start.

If you have been wondering whether tirzepatide is right for you and how your cycle might be affected, the clearest next step is a free clinical assessment. Start your free consultation and speak to a prescriber who can look at your full picture.